cFLIP Emerges as a Novel Therapeutic Target in Relapsed/Refractory DLBCL

Emerging data published in Blood reveal that cellular FADD-like IL-1β–converting enzyme–like inhibitory protein (cFLIP) expression in B cells is essential for the development of diffuse large B-cell lymphoma (DLBCL). These findings show that deletion of cFLIP restores extrinsic apoptosis and sensitizes lymphoma cells to cell death signals, identifying cFLIP as a promising therapeutic target, particularly for patients with relapsed or refractory disease who have limited treatment options.¹

DLBCL and the Role of Apoptosis

DLBCL is the most common subtype of non-Hodgkin lymphoma, identified by a significant molecular heterogeneity and variable clinical outcomes.² While initial therapies such as R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride [hydroxydaunomycin], vincristine sulfate [Oncovin] and prednisone) induce remission in many patients, a considerable amount experience relapse or develop refractory disease.³ These patients often face poor prognoses, emphasizing the need for novel therapeutic strategies.

A defining characteristic of DLBCL is the evasion of apoptosis, allowing malignant B cells to persist and proliferate despite normal cellular death signals. Previous data primarily focused on disruptions in the intrinsic (mitochondrial) apoptosis pathway, particularly the overexpression of antiapoptotic proteins such as BCL2 that enable malignant B cells to evade programmed cell death.⁴ However, the extrinsic apoptosis pathway, which is mediated by death receptors such as tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) receptors, has remained less well understood in lymphoma biology.

A key regulator of extrinsic apoptosis is cFLIP, encoded by the CFLAR gene. cFLIP inhibits caspase-8 activation, thereby preventing death receptor–mediated apoptosis.⁵ These data highlight that cFLIP is not merely supportive but essential for lymphoma development under oncogenic conditions.

Mechanism of Action: cFLIP as a Therapeutic Target

The data showed that the genetic deletion of CFLAR in B cells prevented lymphoma formation in a murine model driven by oncogenic MYD88 signaling and BCL2 overexpression. This finding implies that the suppression of intrinsic apoptosis alone is insufficient for lymphomagenesis unless extrinsic apoptosis is simultaneously inhibited.¹

Loss of cFLIP selectively sensitized activated B-cell (ABC) subtype cells but not germinal center B-cell (GCB) subtype cells to TRAIL- and lipopolysaccharide (LPS)-induced apoptosis via caspase-8 activation in human DLBCL cell lines. This subtype-specific vulnerability highlights a potential precision medicine approach.¹

Subsequently, FLIP was revealed to regulate inflammatory signaling independent of its role in apoptosis, suppressing proinflammatory cytokine transcription in ABC DLBCL. Targeting cFLIP could influence both tumor survival and the tumor microenvironment as shown by this dual function.¹

Study Findings

The research was conducted using murine models, CRISPR (clustered regularly interspaced short palindromic repeats)–mediated gene editing, and analyses of human lymphoma cell lines. The following key findings were unveiled¹:

• B cell–specific deletion of CFLAR prevented DLBCL development in vivo;
• cFLIP loss restored sensitivity to extrinsic apoptosis despite ongoing intrinsic pathway suppression;
• ABC DLBCL cells showed increased susceptibility to TRAIL-mediated apoptosis following cFLIP depletion, whereas GCB cells did not; and
• cFLIP plays a role in modulating inflammatory cytokine expression, particularly in ABC DLBCL.

These findings show that effective lymphomagenesis requires coordinated suppression of both intrinsic and extrinsic apoptosis pathways.

cFLIP: A New Frontier in Overcoming Apoptosis Resistance in DLBCL

The identification of cFLIP as a critical regulator of DLBCL pathogenesis represents a significant advancement in the comprehension of lymphoma biology. By demonstrating that inhibition of extrinsic apoptosis is required for tumor development, these data support novel therapeutic approaches aimed at restoring programmed cell death.¹

REFERENCES

1. Bariboloka KT, Serrano-Saenz S, Savcigil DP, et al. Expression of cFLIP in B cells is essential for diffuse large B-cell lymphoma pathogenesis. Blood. Published online April 23, 2026. doi:10.1182/blood.2026033320

2.Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384(9):842-858. doi:10.1056/nejmra2027612

3.Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808. doi:10.1182/blood-2017-03-769620

4.Czabotar P, Lessene G, Strasser A, et al. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15:49-63. doi:10.1038/nrm3722

5.Shirley S, Micheau O. Targeting c-FLIP in cancer. Cancer Lett. 2013;332(2):141-150. doi:10.1016/j.canlet.2010.10.009‌